Atossa Therapeutics (ATOS) Non-Current Assets (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Non-Current Assets of $1.3 million for Q1 2026, down 36.35% year-over-year from $2.0 million in Q1 2025, and down 35.93% quarter-over-quarter from $2.0 million in Q4 2025.
Atossa Therapeutics (ATOS) Non-Current Assets (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Non-Current Assets for 16 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 36.35% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $7.6 million (down 27.62% YoY), while the FY2025 annual figure was $2.0 million, changed 0.15% from the prior year.
- Non-Current Assets slipped to $1.3 million in Q1 2026 per ATOS's latest filing, from $2.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $5.3 million in Q4 2022 and bottomed at $627000.0 in Q2 2022.
- Historically, Non-Current Assets has averaged $2.8 million across 5 years, with a median of $2.4 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 24150.0% — and 2025, when it sank 51.74%.
- Atossa Therapeutics' Non-Current Assets stood at $5.3 million in 2022, then retreated by 24.4% to $4.0 million in 2023, then tumbled by 50.73% to $2.0 million in 2024, then grew by 0.15% to $2.0 million in 2025, then plunged by 35.93% to $1.3 million in 2026.
- Business Quant data shows ATOS's Non-Current Assets at $1.3 million in Q1 2026, $2.0 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.27 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 4.03 Mn |
| Dec 31, 2023 | 4.03 Mn |
| Sep 30, 2023 | 4.05 Mn |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 5.33 Mn |
| Dec 31, 2022 | 5.34 Mn |
| Sep 30, 2022 | 3.33 Mn |
| Jun 30, 2022 | 627,000.00 |
| Mar 31, 2022 | 630,000.00 |
| Dec 31, 2021 | 22,000.00 |
| Sep 30, 2021 | 36,763.00 |